VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. sold 4.0% of their position (214.63K shares) of KALVISTA PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $3.69M — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 5 sales
Filed: 3/27/2026ACC: 0001231919-26-000286
→
10% Owner
Since Sep 2018
-214.63K
Net shares
Net seller
$3.69M
Total sold
5
Open market trades
0B · 5S
5
Total transactions
214.63K disposed
Non-Derivative Transactions5
Common Stock
Indirect
Shares
−174.49K
Price / share
$16.95
Trade value
$2.96M
% of position
3.3%
3/25/2026
5.30M→5.13M
Common Stock
Indirect
Shares
−160.00
Price / share
$17.53
Trade value
$2.80K
% of position
0.0%
3/25/2026
5.13M→5.13M
Common Stock
Indirect
Shares
−21.39K
Price / share
$17.76
Trade value
$379.82K
% of position
0.4%
3/26/2026
5.13M→5.11M
Common Stock
Indirect
Shares
−15.42K
Price / share
$18.82
Trade value
$290.15K
% of position
0.3%
3/26/2026
5.11M→5.09M
Common Stock
Indirect
Shares
−3.18K
Price / share
$19.12
Trade value
$60.86K
% of position
0.1%
3/26/2026
5.09M→5.09M
Total
Net shares
−214.63K
Net value
-$3.69M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 3/25/2026 | S · Sale | −174.49K | $16.95 | $2.96M | 3.3% | 5.30M | 5.13M |
| Common Stock Indirect | 3/25/2026 | S · Sale | −160.00 | $17.53 | $2.80K | 0.0% | 5.13M | 5.13M |
| Common Stock Indirect | 3/26/2026 | S · Sale | −21.39K | $17.76 | $379.82K | 0.4% | 5.13M | 5.11M |
| Common Stock Indirect | 3/26/2026 | S · Sale | −15.42K | $18.82 | $290.15K | 0.3% | 5.11M | 5.09M |
| Common Stock Indirect | 3/26/2026 | S · Sale | −3.18K | $19.12 | $60.86K | 0.1% | 5.09M | 5.09M |
| Total | −214.63K | -$3.69M | ||||||
Derivative Transactions0
No derivative transactions reported